Last reviewed · How we verify
Indium-111 pentetreotide
Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors.
Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors. Used for Diagnostic imaging of neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors), Localization of somatostatin receptor-positive tumors.
At a glance
| Generic name | Indium-111 pentetreotide |
|---|---|
| Also known as | NeuroendoMedix |
| Sponsor | Radio Isotope Therapy of America |
| Drug class | Radiolabeled somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Pentetreotide is a synthetic octapeptide that mimics somatostatin and binds with high affinity to somatostatin receptors (particularly subtypes 2 and 5) that are overexpressed on neuroendocrine tumors. When labeled with the gamma-emitting radioisotope Indium-111, it enables single-photon emission computed tomography (SPECT) imaging to detect and localize somatostatin receptor-positive tumors throughout the body. This allows clinicians to identify primary tumors, metastases, and assess receptor expression for potential therapeutic targeting.
Approved indications
- Diagnostic imaging of neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors)
- Localization of somatostatin receptor-positive tumors
Common side effects
- Flushing
- Abdominal pain
- Diarrhea
- Nausea
Key clinical trials
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors (PHASE2, PHASE3)
- Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT (PHASE2)
- Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis (NA)
- Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor (PHASE3)
- Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors (PHASE4)
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors (PHASE1, PHASE2)
- Combination Targeted Radiotherapy in Neuroendocrine Tumors (NA)
- Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indium-111 pentetreotide CI brief — competitive landscape report
- Indium-111 pentetreotide updates RSS · CI watch RSS
- Radio Isotope Therapy of America portfolio CI